News & Events

United States FDA Alerts Pet Owners and Veterinarians of Potential for Neurologic Adverse Events Associated with Certain Flea and Tick Products

October 3, 2018

The U.S. Food and Drug Administration (FDA) posted an alert on September 20, 2018 to pet owners and veterinarians to be aware of the potential for neurologic adverse events in dogs and cats when treated with drugs that are in the isoxazoline class. Read more.
Although this information is for a U.S. audience, the Canadian Veterinary Medical Association is following the issue closely, and asked Health Canada’s Veterinary Drugs Directorate (VDD) for further information and advice.
Health Canada advised the association it is aware of the US FDA’s communication about the adverse reactions in animals associated with the isoxazoline class of drugs used to treat and prevent fleas and ticks in dogs and cats.
The Department indicates that it continues to collaborate with its international regulatory partners and, Health Canada, similar to the US FDA, is working with Canadian manufacturers of drugs belonging to the isoxazoline class to include new label information highlighting that neurological adverse events have been reported in animals receiving this class of drug.
CVMA advises pet owners to consult a veterinarian first if a dog or cat experiences any adverse event while using an isoxazoline product.